Loading clinical trials...
Loading clinical trials...
Investigating Efficacious E-Cigarette Interventions and Cessation Effects on Cancer-Related Biomarkers: A Randomized Trial of Varenicline in Adults
Conditions
Interventions
Varenicline 1mg BID
Placebo
Locations
2
United States
Yale Cancer Center/Smilow Cancer Hospital at Yale-New Haven
New Haven, Connecticut, United States
Hollings Cancer Center at MUSC (HCC)
Charleston, South Carolina, United States
Start Date
October 14, 2025
Primary Completion Date
July 30, 2030
Completion Date
October 30, 2030
Last Updated
December 17, 2025
NCT07466875
NCT01036581
NCT06372899
NCT07214168
NCT06295757
NCT07116837
Lead Sponsor
Yale University
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions